Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor (c-Met or hepatocyte growth factor), ROS1, and anaplastic lymphoma kinase (ALK) tyrosine kinases, which are implicated in the progression of several cancers, including non-small cell lung cancer (NSCLC). Gene rearrangements result in fusion proteins with constitutive activation of the ALK kinase domain. In NSCLC, the most commonly identified fusion partner for ALK in these rearrangements is the 5′-end of the echinoderm microtubule-associated protein-like 4 gene (EML4). According to Pfizer, fusion of the EML4 gene to ALK (also known as an EML4-ALK translocation) has been reported in 3–5% of all NSCLC cases.
4 Drug Overview
5 Product Profiles
5 Xalkori : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
10 Figure 89: Datamonitor Healthcare’s drug assessment summary for dacomitinib in non-small cell lung cancer
12 Figure 91: Dacomitinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
14 Figure 91: Ensartinib for non-small cell lung cancer – SWOT analysis
LIST OF TABLES
5 Table 1: Xalkori drug profile
7 Table 2: Xalkori pivotal trial data in non-small cell lung cancer
9 Table 3: Xalkori late-phase trial data in non-small cell lung cancer
15 Table 4: Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
17 Table 5: Xalkori patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.